Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2005-07-05
2005-07-05
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S423000, C424S426000, C424S428000, C424S484000, C424S485000, C424S486000
Reexamination Certificate
active
06913760
ABSTRACT:
The invention provides a drug delivery compositions and methods for treating pain. A drug delivery composition contains a polymer and at least two drugs sucha as an analgesic agent and an anesthetic agent.
REFERENCES:
patent: 5543156 (1996-08-01), Roorda et al.
patent: 5834010 (1998-11-01), Quan et al.
patent: 6605294 (2003-08-01), Sawhney
patent: 2003/0068371 (2003-04-01), Oshlack et al.
Curley et al, Prolonged Regional Nerve Blockade, Jun. 1996, Anesthesiology, vol. 84 pp. 1401-1410.
Ahmedzai, S., “Current strategies for pain control”, Annals of Oncology, 8: 21-24, 1997.
Bennett, et al., “A peripheral mononeuropathy in rat produces disorders of pain sensation like those seen in man”, Pain, 33(1): 87-107, 1988.
Carr, et al., “Spinal tube of analgesia: Opiods and future options”, Neural Blockade in Clinical Anesthesia and Management of Pain, Cousins and Bridenbaugh, eds., 915-983, 1998.
Chary, et al., “The dose response relationship of controlled-release codeine (codeine contin) in chronic cancer pain”, Journal of Pain and Symptom Management, 9(6): 363-371, 1994.
Cooper, et al., “Patient-controlled extradural analgesia to compare bupivacaine, fentanyl and bupivacaine with fentanyl in the treatment of postoperative pain”, British Journal of Anaesthesia, 70: 503-507, 1993.
Curley, et al., “Prolonged regional nerve blockade”, Anesthesiology, 84(6):1401-1410, 1996.
Dahm, et al., “Six years of continuous infusion of opioid and bupivacaine in the treatment of refractory pain due to intrapelvic extrusion of bone cement after total hip arthroplasty”, Regional Anesthesia and Pain Medicine, 23(3): 315-319, 1998.
Dietz, et al., “Bupivacaine preferentially blocks ventral root axons in rats”, Anesthesiology, 88: 172-180, 1997.
Fletcher, et al., “Antinociceptive effect of bupivacaine encapsulated in Poly(D,L)-Lactide -co-glycotide microspheres in the acute inflammatory pain model of carrageenin-injected rats”, Anesthesia and Analgesia, B4(1) 90-94, 1997.
Grant, et al., “Prolonged analgesia with bupivacaine in a mouse model”, Regional Anesthesia, 19(4): 264-269, 1994.
Hagen, et al., “Comparative clinical efficacy and safety of a novel controlled release oxycodone formulation and controlled-release hydromorphone in treatment of cancer pain”, Cancer, 79(7): 1428-1437, 1997.
Hanks, G.W., “Cancer pain and the importance of its control”, Anti-Cancer Drugs, 6(3): 14-17, 1995.
Hanks, et al., “Opioid responsiveness”, Acta Anaesthesiologica Scandinavica, 41: 154-158, 1997.
Hargreaves, et al., “A new and sensitive method for measuring thermal nociception in cutaneous intrathecal hyperalgesia”, Pain, 32: 77-88, 1988.
Hays, et al., “Comperative clinical efficacy and safety of immediate relese and controlled release hydromorphone for chronic severe cancer pain”. Cancer, 74(6): 1808-1816, 1994.
Lafont, et al., “Use of liposome-associated bupivacaine in a cancer pain syndrome”, Anaesthesia, 51(5):578-579, 1996.
Lawfor, et al., “Dose radio between morphine and hydromorphane in patients with cancer pain: a retrospective study”, Pain, 72(1-2): 79-85, 1997.
Le Corre, et al., “In vitro controlled release kinetics of local anesthetics from poly(D,L-lactide) and poly(lactide-co-glycolide) microspheres”, Journal of Microencapsulation, 14(2): 243-255, 1997.
Lee-Son, et al., “Stereoselective Inhibition of Neuronal Sodium Channels by Local Anesthetics”, Anesthesiology, 77(2): 324-335, 1992.
Lesser, et al., “In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain”, Pain, 65(2-3): 265-272, 1996.
Malinovsky, et al., “Neurotoxicological assestment after intracisternal injection of liposomal bupivacaine in rabbits”, Anesthesia and Analgesia, 85(6): 1331-1336, 1997.
Malinovsky, et al., “Motor and blood pressure effects of epidural sustained release bupivacaine from polymer microspheres: A dose-response study in rabbits”, Anesthesia and Analgesia, 81(3): 519-524, 1995.
Masters, et al., “Sustained local anesthetic release from bioerodible polymer matrices: a potential for prolonged regional analgesia”, Pharmaceutical Research, 10(10): 1527-1532, 1993.
Moulin, et al., “Comparison of continuous subcuateneous and intravenous hydromorphone infusions for management of cancer pain”, The Lancet, 337: 465-468, 1991.
Parker, et al., “Epidural patient-controlled analgesia: influence of bupivacaine and hydromorphone basal infusion on pain control after cesarean delivery”, Anesthesia and Analgesia, 75(5): 740-746, 1992.
Payne, R., “Factor influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain”, Seminars in Oncology, 25(3): 47-53,1998.
Renck, et al., “Slow release formulations of local anesthetics and opioids”, Current in Anesthesiology, 9: 399-403, 1996.
Rhodes, et al., “Hydromorphone Polymer Implant”, Journal of Substance Abuse Treatment, Journal of Substance Abuse Treatment, 14(6): 535-542, 1997.
Singh, et al., “Effects of ketorolac versus bupivacaine co-administration during patient-controlled hydromorphone epidural analgesia after thoracotomy procedures”, Anesthesia and Analgesia, 84(3), 564-569, 1997.
Sjoberg, et al., “Nueropathologic findings after long-term intrathecal infusion of morphine and bupivacaine for pain treatment in cancer patients”, Anesthesiology, 76(2): 173-186, 1992.
Suri, et al., “Pharmacokinetic-pharmacodynamic relationships for analgesics”, International Journal of Clinical Pharmacology and Therapeutics, 35(8):307-323, 1997.
Vainio, et al., “Opioid treatment for radiating cancer pain: oral administration vs. epidural techniques”, Acta Anesthesiologica Scandinavica, 32: 179-185, 1988.
van Dongan, et al., “Neurological impairment during long-term intrathecal infusion of bupivacaine in cancer patients: a sign of spinal cord compression”, Pain, 69(1-2): 205-209, 1997.
Vercauteren, et al., “Addition of bupivacaine to sulfentanil in patient controlled epidural analgesia after lower limb surgery in young adults”, Regional Anesthesia and Pain Medicine, 23(2): 182-188, 1998.
Vigano, et al., “Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators”, Pain, 67(1): 115-119, 1996.
Wu, et al., “The efficacy of intrathecal coadministration of morphine and bupivacaine for labor analgesia”, Acta Anaesthesiologica Scandinavica, 35: 209-216, 1997.
Okuda, et al., “Prolonged antinociceptive effect of poly (DL-lactic acid)-fentanyl composites after their intrathecal injection in rats” (in Japanese), Masui—Japanese Journal of Anesthesiology, 48(2): 141-145, 1999, with Abstract in English.
Carr Daniel B.
Hasirci Vasif
Lipkowski Andrzej W.
Wise Donald L.
Beattie, Esq. Ingrid A.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
New England Medical Hospitals, Inc.
Pryor Alton
LandOfFree
Drug delivery composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug delivery composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug delivery composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3419208